James C. Clemmer - Jul 14, 2021 Form 4/A - Amendment Insider Report for ANGIODYNAMICS INC (ANGO)

Role
President and CEO, Director
Signature
/s/ Richard C. Rosenzweig, Attorney in Fact
Stock symbol
ANGO
Transactions as of
Jul 14, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
12/30/2021, 04:59 PM
Date Of Original Report
Jul 23, 2021
Next filing
Jul 27, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANGO Common Stock Award $0 +37.4K +11.17% $0.00 373K Jul 21, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANGO Performance Right Award $0 +74.8K $0.00 74.8K Jul 21, 2021 Common Stock 74.8K Direct F1, F3
transaction ANGO Non-Qualified Stock Option (right to buy) Award $0 +102K $0.00 102K Jul 21, 2021 Common Stock 102K $26.49 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.
F2 The acquisition of 37,420 shares of common stock ("Common Stock") of the Company represents 37,420 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.
F3 Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
F4 These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.